[1]陈丽丽,施民新,薛丽娟.剪接因子3B亚单位1在乳腺癌组织中的表达及与患者临床病理特征关系[J].陕西医学杂志,2024,(2):262-265.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.025]
　CHEN Lili,SHI Minxin,XUE Lijuan.Expression of SF3B1 in breast cancer tissues and its relationship with clinicopathology[J].,2024,(2):262-265.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.025]
点击复制

剪接因子3B亚单位1在乳腺癌组织中的表达及与患者临床病理特征关系
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年2期
页码:
262-265
栏目:
临床病理
出版日期:
2024-02-05

文章信息/Info

Title:
Expression of SF3B1 in breast cancer tissues and its relationship with clinicopathology
作者:
陈丽丽; 施民新; 薛丽娟
(南通市肿瘤医院 南通大学附属肿瘤医院,江苏 南通 226000)
Author(s):
CHEN Lili; SHI Minxin; XUE Lijuan
(Nantong Tumor Hospital,Nantong 226000,China)
关键词:
乳腺癌;  剪接因子3B亚单位1;  诊断;  临床病理;  淋巴结转移;  受试者工作特征曲线
Keywords:
Breast cancer;  Splicing factor 3B subunit 1;  Diagnosis;  Clinicopathology;  Lymph node metastasis;  Receiver operating characteristic curve
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2024.02.025
文献标志码:
A
摘要:
目的:探讨剪接因子3B亚单位1(SF3B1)在乳腺癌组织中的表达及与患者临床病理特征的关系。方法:分析88例乳腺癌患者乳腺癌组织和癌旁组织SF3B1的表达水平,评估SF3B1对乳腺癌的诊断价值,比较SF3B1高表达组与低表达组临床病理特征差异。结果:乳腺癌组织SF3B1表达明显高于癌旁组织(P<0.05); SF3B1诊断乳腺癌的AUC为0.713; SF3B1诊断乳腺癌的最佳截断值为110.72。高表达组年龄明显高于低表达组,淋巴结转移为N0的比例明显低于低表达组,两组病理学分级比较差异有统计学意义(P<0.05)。结论:SF3B1在乳腺癌组织中的表达明显上调,在诊断乳腺癌方面效能较好,与临床病理参数有关,可能参与了乳腺癌的发生、侵袭和转移过程的调控。
Abstract:
Objective:To analyze the expression of splicing factor 3B subunit 1(SF3B1)in breast cancer tissues and its relationship with clinicopathology.Methods:The expression levels of SF3B1 in breast cancer tissues and adjacent non-tumor tissues were compared in 88 breast cancer patients,evaluate the diagnostic value of SF3B1 for breast cancer.The differences in clinicopathological characteristics between the high- and low-SF3B1 expression groups were compared.Results:The expression of SF3B1 in breast cancer tissues was significantly higher than that in adjacent tissues(P<0.05).The AUC of SF3B1 for diagnosis of breast cancer was 0.713.The best cut-off value of SF3B1 for the diagnosis of breast cancer was 110.72.The age of the high-SF3B1 expression group was significantly higher than that of the low-SF3B1 expression group,the proportion of lymph node metastasis to N0 was significantly lower than that of the low-SF3B1 expression group,and there was significant difference in pathological grade between the two groups(all P<0.05).Conclusion:The expression of SF3B1 is significantly up-regulated in breast cancer tissues and has a good diagnostic efficacy in breast cancer.SF3B1 is related to clinicopathological parameters and may be involved in the regulation of the occurrence,invasion and metastasis of breast cancer.

参考文献/References:

[1] 曹君红,陈蒙,贾琦,等.剪接因子异质核糖核蛋白A2B1在癌细胞和衰老细胞中的相反表达趋势及其对癌细胞衰老的调控[J].中国生物化学与分子生物学报,2021,37(1):66-75.
[2] 黎立喜,温霆宇,管秀雯,等.早发性乳腺癌的遗传易感基因及临床特征[J].国际肿瘤学杂志,2022,49(4):206-209.
[3] 邹腾跃,邹芳芳,孙亚君,等.烟酰胺磷酸核糖基转移酶及沉默信息调节因子2同源蛋白1在乳腺癌组织中的表达及与患者临床病理特征的关系[J].陕西医学杂志,2023,52(8):1093-1101.
[4] 伊茹,蔡凤林,符德元.环状RNA的生物学功能及其在不同分子分型乳腺癌中的研究进展[J].医学综述,2022,28(3):483-487.
[5] 郑葆龙,谢小薰,肖绍文.选择性剪接与肿瘤靶向治疗[J].生理科学进展,2021,52(2):100-102.
[6] 闫雷,杨洋.缺氧相关长链非编码RNA与乳腺癌患者预后的相关性及其在预测乳腺癌预后的风险中的价值[J].广西医学,2021,43(22):2678-2683.
[7] 韩艳春,荆丽丽,石佳宁,等.RASSF7表达与乳腺癌上皮-间质转化的关系[J].临床与实验病理学杂志,2021,37(1):13-17.
[8] 王奕丹,王一涵,黄钰雯,等.DNA甲基转移酶3b对乳腺癌细胞微小RNA表达的影响[J].中国医科大学学报,2021,50(2)116-123.
[9] 张慧峰,李茉,许淑娣,等.拉帕替尼治疗HER2阳性局部晚期乳腺癌临床疗效研究[J].陕西医学杂志,2023,52(5):596-599.
[10] 赵春艳,胡先华,张人丹,等.烯醇化酶mRNA表达在乳腺癌患者中的预后判断价值[J].重庆医学,2020,49(9):1510-1514.
[11] 冯秀梅,马兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,42(11):1527-1530.
[12] MAGUIRE S L,LEONIDOU A,WAI P,et al.SF3B1 mutations constitute a novel therapeutic target in breast cancer[J].J Pathol,2015,235(4):571-580.
[13] LAWRENCE M S,STOJANOV P,MERMEL C H,et al.Discovery and saturation analysis of cancer genes across 21 tumour types[J].Nature,2014,505(7484):495-501.
[14] 刘丹,胥旸,邢晓静.鸦胆子苦醇对三阴性乳腺癌细胞凋亡的影响[J].陕西中医,2021,42(4):419-422.
[15] 刘婧思,陈久安,孙洁,等.DNA损伤修复基因胚系突变乳腺癌新辅助化疗疗效分析[J].中国肿瘤临床,2023,50(10):497-503.
[16] 李晓亚,单保恩,赵连梅.基因可变剪接在癌症发生和治疗中的研究进展[J].中国肿瘤生物治疗杂志,2019,26(9):1042-1048.
[17] 吴志懂,覃俊仕,肖顺崇,等.卡培他滨节拍化疗对早期非激素依赖型乳腺癌预后及复发风险的影响研究[J].陕西中医,2021,42(1):74-75.
[18] 毋艳,刘晓娟,王慧.45例骨髓增生异常综合征患者SF3B1、TET2、RUNX1及TP53基因突变分析[J].实用肿瘤杂志,2018,33(3):76-78.
[19] 杜森,赵森,周青,等.血清长链非编码RNA小核仁RNA宿主基因3检测联合核磁共振弥散加权成像在乳腺癌诊断中的应用[J].陕西医学杂志,2022,51(8):1021-1024,1037.
[20] SAMY A,OZDEMIR M K,ALHAJJ R.Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research [J].Sci Rep,2023,13(1):2704.
[21] LI X,LIU D,WANG Y,et al.PHF5A as a new oncotarget and therapeutic prospects [J].Heliyon,2023,9(7):18010.
[22] 任俊玲,陈斌,程伟波.BRAFV600E基因突变和TERT启动子突变与甲状腺微小乳头状癌中央区淋巴结转移的关系[J].皖南医学院学报,2021,40(4):362-365.
[23] 王锴,郭向婷,宗守凯.C反应蛋白、白蛋白、血小板/淋巴细胞比率与乳腺癌患者病理特征、新辅助化疗疗效的相关性[J].川北医学院学报,2022,37(8):1032-1036.
[24] 陈金蓉,唐小涵,陈仕高,等.乳腺癌雌激素受体和人类表皮生长因子受体-2联合表达与淋巴结转移相关性分析[J].成都医学院学报,2022,17(6):702-705.
[25] 王圆,徐方名,许俊德,等.乳腺癌驱动基因及其精准治疗研究进展[J].中国药理学通报,2021,37(7):889-892.

相似文献/References:

[1]王 敏,李习平,杨 梅,等.Caspase信号途径及其在乳腺癌治疗中的作用研究进展[J].陕西医学杂志,2021,50(3):377.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.032]
　WANG Min,LI Xiping,YANG Mei,et al.Research progress on Caspase signaling pathway and its role in treatment of breast cancer[J].,2021,50(2):377.[doi:DOI:10.3969/j.issn.1000-7377.2021.03.032]
[2]崔 杰,刘 鑫.纤维蛋白原与白蛋白比值与激素受体阳性/人类表皮生长因子受体2阴性乳腺癌新辅助化疗疗效相关性分析[J].陕西医学杂志,2022,51(11):1351.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.007]
　CUI Jie,LIU Xin.Correlation between fibrinogen to albumin ratio and efficacy of neoadjuvant chemotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer[J].,2022,51(2):1351.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.007]

备注/Memo

备注/Memo:
基金项目:江苏省卫生健康委员会医学科研立项课题(K2019021)
更新日期/Last Update: 2024-02-05